Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources
03 avr. 2023 08h00 HE
|
Pacira BioSciences
– Term Loan A Carries Significantly Lower Interest Rate – – Meaningfully Improves Debt Leverage Ratio and Reaffirms Outlook for Growth -- TAMPA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- Pacira...
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
29 mars 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
27 mars 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court’s...
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
22 mars 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
08 mars 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare...
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
28 févr. 2023 08h00 HE
|
Pacira BioSciences
— Record revenues of $667 million in 2022 — — Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million — — EXPAREL surpasses the 12 million patient mark — —...
LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions
23 févr. 2023 08h00 HE
|
Pacira BioSciences
DAYTONA BEACH, Fla. and TAMPA, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), a company committed to non-opioid pain management and regenerative health solutions,...
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
21 févr. 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before...
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
05 janv. 2023 16h30 HE
|
Pacira BioSciences
TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM...